Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals Inc (NQ: APLS )

64.82 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 64.82
Bid (Size) 59.00 (2)
Ask (Size) 66.20 (2)
Prev. Close 64.82
Today's Range 64.82 - 64.82
52wk Range 19.83 - 94.45
Shares Outstanding 116,457,008
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Apellis Pharmaceuticals Upgraded To Buy: Analyst Sees Potential In Syfovre's Strong Launch
BofA Securities analyst Tazeen Ahmad upgraded Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) to Buy from Neutral,  
Via Benzinga
14 Analysts Have This to Say About Apellis Pharmaceuticals
Via Benzinga

Performance

YTD
+28.92%
+28.92%
1 Month
+42.62%
+42.62%
3 Month
+50.39%
+50.39%
6 Month
-27.66%
-27.66%
1 Year
+31.27%
+31.27%

More News

Read More
Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Magnificent 7 Take Center Stage In Hedge Fund Portfolios: Analysts Warn Of Extreme Concentration
Via Benzinga
Why Is Apellis Pharmaceuticals Stock Trading Lower Today?
Via Benzinga
21 Analysts Have This to Say About Apellis Pharmaceuticals
Via Benzinga
Analyst Ratings for Apellis Pharmaceuticals
Via Benzinga
Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
NASDAQ:APLS Long Term Investor Notice: Investigation of Potential Wrongdoing at Apellis Pharmaceuticals, Inc.
Via SBWire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90
Via Investor's Business Daily
Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
Via Investor's Business Daily
The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Stocks Mixed Amid Earnings, Consumer Sentiment Data
Via Talk Markets
JPMorgan, Wells Fargo, Citigroup And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Why Pioneer Natural Resources Shares Are Bouncing By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.